Patent application number | Description | Published |
20080238197 | MULTI-MODULE CURRENT SHARING SCHEME - A circuit provides multi-module current sharing for circuit modules. The circuit includes an error amplifier having a negative and a positive input and an output. The positive input of the error amplifier is connected to a reference voltage. A buffered differential amplifier has an output connected to the negative input of the error amplifier and a positive and a negative input. A correction current is sourced to the negative input of the buffered differential amplifier. A resistor connected to the negative input of the buffered differential amplifier has a value that controls the amount of current correction applied to the negative input of the buffer differential amplifier by the current correction source. | 10-02-2008 |
20080238392 | CONTROLLER AND DRIVER COMMUNICATION FOR SWITCHING REGULATORS - Pulse width modulation (PWM) controllers and output stage driver circuits and related methods of communicating switching regulator mode information. The controller includes circuitry that recognizes intervals when the load driven by the regulator is in a low power mode. Responsive to recognizing the low power mode, the controller generates a PWM mode signal having at least three (3) different levels including at least one intermediate level that is coupled to at least one driver. Based on the PWM mode signal, the regulator is switched into a power saving low power operational mode. | 10-02-2008 |
20080272752 | PULSE ADDING SCHEME FOR SMOOTH PHASE DROPPING AT LIGHT LOAD CONDITIONS FOR MULTIPHASE VOLTAGE REGULATORS - A multiphase regulator which includes an output node developing an output voltage, a feedback circuit determining error of the output voltage and providing a compensation signal indicative thereof, at least three phase circuits coupled in parallel to the output node, and an adaptive controller. Each phase circuit includes a modulation circuit and a switch circuit. Each modulation circuit receives the compensation signal and generates pulses on a corresponding one of the pulse modulation signals. Each switch circuit is coupled to the output node and is controlled by a corresponding pulse modulation signal. The adaptive controller is responsive to a load indication signal, such as indicating a low load condition, and drops operation of at least one of the phase circuits and adds at least one pulse to a pulse modulation signal of each remaining phase circuit. | 11-06-2008 |
20100079175 | PHASE DOUBLER - A phase doubler driver circuit includes a first input for receiving a input PWM drive signal. First control logic generates a first output PWM drive signal and a second output PWM drive signal responsive to the input PWM drive signal. In a first mode of operation, alternating pulses of the input PWM drive are output as the first output PWM drive signal and the second PWM output drive signal respectively. In a second mode of operation, the input PWM drive signal is provided as the first output PWM drive signal when a second phase current associated with the second output PWM drive signal exceeds a first phase current associated with the first output PWM drive signal and the input PWM drive signal is provided as the second output PWM drive signal when the phase current associated with the first output PWM signal exceed the phase current associated with the second output PWM signal. Second control logic adds an offset to a falling edge of the first output PWM drive signal responsive to a difference between a first current associated with the first phase current and an average current and for adding the offset to a falling edge of the second output PWM signal responsive to a difference between a second current associated with the second phase current and the average current, wherein the average current comprises the average of the first current and the second current. Drive circuitry generates drive signals responsive to each of the first output PWM drive signal and the second output PWM drive signal. | 04-01-2010 |
20100171645 | N-BIT ADC READER - An integrated circuit including a single input pin for determining a value associated with a resistor divider. The circuit includes first circuitry for determining a resistor ratio of the resistor divider through the single input pin. A first register stores a first group of bits representing the resistor ratio. The first group of bits comprises the least significant bits of the value. Second circuitry determines an equivalent resistance of the resistor divider through the single input pin. A second register stores a second group of bits representing the equivalent resistance. The second group of bits comprises the most significant bits of the value associated with the resistor divider. | 07-08-2010 |
20100283523 | CONTROLLER AND DRIVER COMMUNICATION FOR SWITCHING REGULATORS - Pulse width modulation (PWM) controllers and output stage driver circuits and related methods of communicating switching regulator mode information. The controller includes circuitry that recognizes intervals when the load driven by the regulator is in a low power mode. Responsive to recognizing the low power mode, the controller generates a PWM mode signal having at least three ( | 11-11-2010 |
20100320977 | PULSE ADDING SCHEME FOR SMOOTH PHASE DROPPING AT LIGHT LOAD CONDITIONS FOR MULTIPHASE VOLTAGE REGULATORS - A pulse control system for a multiphase regulator including an error amplifier, a multiphase generator, and an adaptive controller. The error amplifier provides an error signal indicative of output voltage error. The multiphase generator develops modulation pulses for phases based on the error signal. The adaptive controller is responsive to a load indication signal and redirects at least one modulation pulse from a first of phase to a second phase. The load indication signal may be received from a microprocessor indicating a low power mode. The adaptive controller provides a smooth and efficient transition to low load conditions by dropping operation of one or more phases and redirecting modulation pulses to the remaining one or more phases, and reduced phases improve power efficiency for the low load conditions. | 12-23-2010 |
20110133716 | CONTROLLER AND DRIVER COMMUNICATION FOR SWITCHING REGULATORS - Pulse width modulation (PWM) controllers and output stage driver circuits and related methods of communicating switching regulator mode information. The controller includes circuitry that recognizes intervals when the load driven by the regulator is in a low power mode. Responsive to recognizing the low power mode, the controller generates a PWM mode signal having at least three (3) different levels including at least one intermediate level that is coupled to at least one driver. Based on the PWM mode signal, the regulator is switched into a power saving low power operational mode. | 06-09-2011 |
20110133717 | CONTROLLER AND DRIVER COMMUNICATION FOR SWITCHING REGULATORS - Pulse width modulation (PWM) controllers and output stage driver circuits and related methods of communicating switching regulator mode information. The controller includes circuitry that recognizes intervals when the load driven by the regulator is in a low power mode. Responsive to recognizing the low power mode, the controller generates a PWM mode signal having at least three (3) different levels including at least one intermediate level that is coupled to at least one driver. Based on the PWM mode signal, the regulator is switched into a power saving low power operational mode. | 06-09-2011 |
20110204947 | METHOD AND APPARATUS FOR ADAPTIVELY MODIFYING A PULSE WIDTH OF A PULSE WIDTH MODULATED OUTPUT - Systems, methods, and apparatus for improving steady state operation of a pulse width modulator during transient and soft start events are described herein. An apparatus can include a phase component configured to adaptively modify a pulse width of a first pulse width modulated (PWM) output signal based on a pulse width of a PWM input signal. Further, the apparatus can include a power stage component configured to source at least one of a voltage or a current to a load based on the first PWM output signal. In one example, the phase component can be configured to linearly extend the pulse width of the first PWM output signal based on the pulse width of the PWM input signal. In another example, the phase component can be configured to adaptively modify the pulse width of the first PWM output signal based on a predetermined maximum pulse width. | 08-25-2011 |
20110241640 | SYSTEM AND METHOD OF INTERMITTENT DIODE BRAKING FOR MULTIPLE PHASE VOLTAGE REGULATOR - A method of operating a regulator controller IC for performing intermittent diode braking for controlling a multiple phase voltage regulator. The method includes receiving at least one signal for detecting repetitive load transients, determining a rate of the repetitive load transients, generating diode braking control signals, each for applying diode braking to a corresponding one of multiple phases for at least one load transient when the repetitive load transients are below a first rate, and controlling the diode braking control signals to drop application of diode braking of at least one phase for at least one load transient when the repetitive load transients are at least the first rate. The method may include rotating the application of diode braking among the phases during successive applications of diode braking. The method may include dropping an increased number of phases for diode braking as the rate of repetitive load transients is increased. | 10-06-2011 |
20140197811 | CURRENT LIMITING SCHEME FOR A CONVERTER - A modulator configured to control switching of current through an inductor of a converter according to a current limiting scheme while converting an input voltage to an output voltage, which includes a current limit generator and a comparator network. The current limit generator is configured to provide a periodic ramping current limit value based on either the input voltage or the output voltage, an inductance of the inductor, a timing signal, and a predetermined maximum output current of the boost converter. The comparator network is configured to provide a switch control signal to control switching of current through the inductor by comparing a current sense value indicative of a current through the inductor with a lesser of a compensation error value and the periodic ramping current limit value. The converter may be configured as a peak current mode control converter in either boost or buck mode. | 07-17-2014 |
Patent application number | Description | Published |
20090023142 | Methods for Detecting Minimum Residual Disease - The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject. | 01-22-2009 |
20130216528 | Anti-GD2 Antibodies - In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma. | 08-22-2013 |
20140024809 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 01-23-2014 |
20140296492 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 10-02-2014 |
Patent application number | Description | Published |
20100216743 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 08-26-2010 |
20100226914 | METHOD FOR PREPARATION OF SINGLE CHAIN ANTIBODIES - This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods. | 09-09-2010 |
20100273867 | THERAPY-ENHANCING GLUCAN - A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed. | 10-28-2010 |
20100284920 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative. | 11-11-2010 |
20100310571 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 12-09-2010 |
20110195071 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 08-11-2011 |
20130183295 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 07-18-2013 |
20130230535 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 09-05-2013 |
20130287798 | USES OF MONOCLONIAL ANTIBODY 8H9 - This invention provides an antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the heavy chain CDR (Complementary Determining Region)1 comprises NYDIN, heavy chain CDR2 comprises WIFPGDGSTQY, heavy chain CDR3 comprises QTTATWFAY, and the light chain CDR1 comprises RASQSISDYLH, light chain CDR2 comprises YASQSIS, and light chain CDR3 comprises QNGHSFPLT. In another embodiment, there is provided a polypeptide that binds the same antigen as that of monoclonal antibody 8H9, wherein the polypeptide comprises NYDIN, WIFPGDGSTQY, QTTATWFAY, RASQSISDYLH, YASQSIS, and QNGHSFPLT. | 10-31-2013 |
20130289101 | THERAPY-ENHANCING GLUCAN - A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed. | 10-31-2013 |
20140161814 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 06-12-2014 |
20140335100 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 11-13-2014 |
Patent application number | Description | Published |
20090129647 | METHODS AND SYSTEMS FOR IDENTIFICATION OF DNA PATTERNS THROUGH SPECTRAL ANALYSIS - Spectrogram extraction from DNA sequence has been known since 2001. A DNA spectrogram is generated by applying Fourier transform to convert a symbolic DNA sequence consisting of letters A, T, C, G into a visual representation that highlights periodicities of co-occurrence of DNA patterns. Given a DNA sequence or whole genomes, with this method it is easy to generate a large number of spectrogram images. However, the difficult part is to elucidate where are the repetitive patterns and to associate a biological and clinical meaning to them. The present disclosure provides systems and methods that facilitate the location and/or identification of repetitive DNA patterns, such as CpG islands, Alu repeats, tandem repeats and various types of satellite repeats. These repetitive elements can be found within a chromosome, within a genome or across genomes of various species. The disclosed systems and methods apply image processing operators to find prominent features in the vertical and horizontal direction of the DNA spectrograms. Systems and methods for fast, full scale analysis of the derived images using supervised machine learning methods are also disclosed. The disclosed systems and methods for detecting and/or classifying repetitive DNA patterns include: (a) comparative histogram method, (b) feature selection and classification using support vector machines and genetic algorithms, and (c) generation of spectrovideo from a plurality of spectral images. | 05-21-2009 |
20100050227 | Update Process for Interface Device Based Targeted Information Insertion - Advertisements or other types of targeted information are delivered to set-top boxes or other user interface devices of a signal distribution system. In one aspect of the invention, at least one multicast update comprising updated targeted information is sent to the user interface devices during a multicast update period. If a given one of the user interface devices is unable to obtain a complete set of the updated targeted information from the multicast update before timeout of the multicast update period, a unicast update comprising at least a portion of the updated targeted information is sent to the given user interface device during a unicast update period. The unicast update may be sent responsive to a request from the given user interface device for a designated portion of the updated targeted information. | 02-25-2010 |